# A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

> **NCT03670030** · PHASE2 · TERMINATED · sponsor: **Robert Ramirez** · enrollment: 5 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** ABI-009

## Key facts

- **NCT ID:** NCT03670030
- **Lead sponsor:** Robert Ramirez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-05
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-02-26
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03670030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03670030, "A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03670030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*